Apostle invents best-in-class technologies to work with circulating free DNA (cfDNA)
, a key element in liquid biopsy
. Since Feb 2019, Apostle
has entered a partnership with Beckman Coulter Life Sciences
to provide access to our innovative cfDNA isolation products
globally.
Background
Circulating free DNA (cfDNA) are degraded DNA fragments released to the blood plasma after diseased or normal cells die.
cfDNA can be used to describe various forms of DNA freely circulating the bloodstream, including circulating tumor DNA (ctDNA)
and cell-free fetal DNA (cffDNA) , and therefore, has become a biomarker for cancer and fetal medicine.
In addition, it can be used for a wide range of conditions, including sepsis, aseptic inflammation, transplantation, etc.
A liquid biopsy is the sampling and analysis of non-solid biological tissue, primarily blood,
often utilizing cfDNA as a biomarker.
A liquid biopsy has unleashed the potential to track and monitor important diseases, such as cancer, in a non-invasive and
more effective manner.
Vision
cfDNA is present in very small amounts in the blood plasma. Apostle develops a best-in-class technique, Apostle MiniMaxTM, to efficiently capture this cfDNA from a standard blood draw, as well as other innovations in the space of liquid biopsy. We aim to improve the efficiency and accuracy of liquid biopsy, and consequently, improve the survival rate of patients.
[More readings]
